Recent research indicates that vaccines may play a protective role against dementia—reducing risk rather than increasing it. A landmark meta-analysis of 104 million participants, published in Age and Ageing in 2025, found that adults who received a Tdap vaccination showed a 33% reduction in dementia risk compared to unvaccinated peers. This finding aligns with a systematic review of 16 major studies, where 15 showed vaccinated individuals had lower rates of dementia diagnosis, with risk reductions ranging from 4% to 50% depending on the vaccine and population studied.
The question is no longer whether vaccines influence dementia risk, but rather how and which vaccines offer the most benefit. The current body of evidence suggests that vaccines don’t directly treat or reverse dementia—instead, they appear to reduce the likelihood of developing it in the first place. This protection likely stems from preventing the infections that can trigger chronic inflammation in the brain, a pathway implicated in Alzheimer’s disease and other forms of dementia. For people concerned about cognitive decline, understanding which vaccines offer protection and why is increasingly relevant to brain health discussions.
Table of Contents
- What Do Large-Scale Studies Reveal About Vaccination and Dementia Risk?
- Which Vaccines Offer the Most Dementia Protection?
- How Might Vaccines Protect Brain Health?
- What Do the Most Recent Findings Tell Us About COVID-19 and Cognition?
- Why Haven’t We Moved From Association to Proven Causation?
- Should Older Adults Prioritize Vaccines for Dementia Prevention?
- Infection-Driven Inflammation as a Window into Brain Health
What Do Large-Scale Studies Reveal About Vaccination and Dementia Risk?
The evidence base for vaccines and dementia protection has grown substantially over the past two years. The 2025 meta-analysis examined data across 104 million participants and found consistent associations between specific vaccinations and lower dementia rates. The Tdap vaccine—which protects against tetanus, diphtheria, and pertussis—showed the strongest protective effect in this analysis, with a 33% risk reduction. Pneumococcal vaccination, which prevents infection caused by Streptococcus pneumoniae bacteria, was associated with a 27% reduction in dementia risk. These are not small numbers; a one-third reduction in dementia risk represents a meaningful shift in how we think about preventive care for aging adults.
A parallel systematic review examining 16 randomized and observational studies found that vaccination status was consistently associated with dementia outcomes. In 15 of the 16 studies analyzed, vaccinated adults showed lower dementia rates than their unvaccinated counterparts. The protective effects varied: some studies reported a 4% reduction, while others found risk reductions exceeding 50%. This variation likely reflects differences in which vaccines were studied, the populations examined, and how dementia was diagnosed and confirmed in each study. The consistency across most studies, however, suggests the finding is not due to chance.
Which Vaccines Offer the Most Dementia Protection?
Not all vaccines show equal protection against dementia risk, and the most recent research has identified several standouts. The high-dose influenza vaccine—a formulation designed for older adults—emerged in April 2026 research published in Neurology as one of the most effective options, associated with a 55% reduction in Alzheimer’s disease risk. Standard-dose flu vaccines, by contrast, show approximately 40% risk reduction. This 15-percentage-point difference is significant enough that older adults choosing between vaccine options may want to discuss it with their healthcare provider, particularly if dementia prevention is a concern.
The herpes zoster (shingles) vaccine presents another compelling option. The recombinant zoster vaccine (Shingrix), studied in a cohort of 436,000 participants, was associated with an 18% reduction in dementia diagnoses over an 18-month follow-up period. When researchers focused specifically on Alzheimer’s disease—the most common form of dementia—Shingrix showed a 53% risk reduction. A word of caution: these are observational findings, meaning researchers tracked outcomes in people who chose vaccination versus those who did not, rather than randomly assigning people to receive the vaccine. People who choose to get vaccinated may differ from those who don’t in ways that affect dementia risk, such as overall health status or access to healthcare.
How Might Vaccines Protect Brain Health?
The mechanism by which vaccines reduce dementia risk appears to relate to infection prevention and the inflammatory cascade that infections trigger. Several brain and aging researchers have proposed that chronic or repeated infections—including influenza, pneumococcal disease, and herpes zoster—may initiate or accelerate neuroinflammation, a sustained inflammatory state in the brain. This inflammation is thought to contribute to the accumulation of amyloid-beta and tau proteins, hallmarks of Alzheimer’s pathology. By preventing these infections, vaccines may reduce the brain’s exposure to this inflammatory stimulus.
Herpes simplex virus 1 (HSV-1) and cytomegalovirus (CMV) have drawn particular attention in dementia research because these viruses can remain dormant in neural tissue and periodically reactivate. Some evidence suggests that chronic or recurrent viral reactivation in the brain may worsen neuroinflammation and accelerate cognitive decline. Vaccines that prevent primary infection or reduce reinfection frequency could theoretically interrupt this cycle. However, it’s important to note that we do not yet have evidence of vaccine neurotoxicity or direct harmful effects on the brain from any routine vaccine. No recent epidemiological review identified vaccine components as a cause of dementia development.
What Do the Most Recent Findings Tell Us About COVID-19 and Cognition?
A 2025 analysis of adults with existing cognitive disorders examined outcomes in 25,733 participants, comparing vaccinated and unvaccinated individuals. Vaccinated older adults with cognitive impairment showed reduced mortality risk, though this finding requires careful interpretation because vaccinated and unvaccinated groups may have differed in other health factors. A machine learning analysis of 10,000 study participants found that vaccinated individuals experienced approximately 1.2 points less annual cognitive decline, measured on the Mini-Cog screening tool. While 1.2 points per year may seem modest, over a decade this could represent meaningful preservation of cognitive function.
These COVID-19 findings differ from the influenza and shingles data in an important way: most COVID-19 vaccine research has focused on mortality and severe illness rather than dementia risk. The cognitive decline data come from smaller, observational studies rather than the large meta-analyses available for other vaccines. This is partly because COVID-19 vaccines are recent, and dementia development typically unfolds over years or decades. Researchers will need longer follow-up periods to assess whether COVID-19 vaccination is associated with reduced dementia incidence as people age.
Why Haven’t We Moved From Association to Proven Causation?
The research showing associations between vaccines and lower dementia risk represents important epidemiological evidence, but epidemiology cannot prove that one thing causes another—only that two factors are statistically linked. To prove that a vaccine directly reduces dementia risk, researchers would ideally conduct randomized controlled trials, where some older adults randomly receive a vaccine and others receive a placebo, followed over many years to compare dementia rates. Such trials are expensive, lengthy, and face ethical challenges because we already have evidence suggesting vaccines may be beneficial. For practical and ethical reasons, trials of this scale have not been conducted for dementia prevention.
A second limitation is the healthy-user bias: people who choose to get vaccinated often differ from those who don’t in ways that affect health outcomes. Vaccinated individuals may exercise more, attend medical appointments regularly, have better nutrition, or be in better overall health at the time vaccination occurred. Some of the apparent dementia protection attributed to vaccines might actually reflect these other health factors. Statistical methods can partly account for these differences, but they cannot fully eliminate this source of bias. Researchers continue to refine their analysis methods to isolate the vaccine’s effect from these confounding factors.
Should Older Adults Prioritize Vaccines for Dementia Prevention?
Current dementia prevention strategies include cognitive exercise, physical activity, social engagement, cardiovascular health management, and cognitive behavioral interventions for depression. Vaccination is emerging as a component of this broader picture rather than a standalone solution. For older adults, the decision to prioritize specific vaccines should rest on established guidelines from organizations like the CDC and recommendations from a healthcare provider, rather than solely on dementia prevention. However, if dementia risk is a particular concern—for example, if there is a family history of Alzheimer’s disease—discussing vaccine options with a physician makes sense.
The high-dose influenza vaccine offers a concrete example of how dementia prevention considerations might inform vaccine choice. Medicare covers both standard-dose and high-dose flu vaccines for adults age 65 and older. An older adult worried about cognitive decline could reasonably ask their doctor whether high-dose influenza vaccination might be appropriate given the 55% risk reduction observed in recent research. Similarly, shingles vaccination (Shingrix) is recommended for all adults age 50 and older, and the 53% Alzheimer’s risk reduction observed in one study provides additional motivation for those who have not yet been vaccinated.
Infection-Driven Inflammation as a Window into Brain Health
The emerging picture linking infections to dementia risk has shifted how researchers think about preventive medicine in aging. Rather than viewing dementia as purely a problem of aging itself, researchers increasingly recognize repeated infections and chronic inflammation as modifiable risk factors. This perspective suggests that seemingly unrelated infections—a bout of pneumonia, recurrent urinary tract infections, or herpes zoster—may have downstream effects on cognitive health. Vaccines prevent these infections and their inflammatory consequences, potentially affecting brain aging.
This understanding carries implications beyond any single vaccine. It suggests that preventing infections broadly—through vaccination, careful hygiene, prompt treatment of illness, and management of chronic conditions like diabetes that impair immune function—contributes to brain health preservation. An older adult focused on dementia prevention might benefit from thinking holistically about infection prevention across the lifespan, with vaccines as one important tool among several. The connection between infection and brain inflammation remains an active research area, and findings over the next few years will likely refine our understanding of which infections pose the greatest dementia risk and which vaccines deserve priority.
